Skip to content

Evaluation of Non-Invasive Hemoglobin in Trauma Patients

Evaluation of Non-Invasive Hemoglobin in Trauma Patients Using FDA-Cleared Masimo Pulse CO-Oximeter

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03123328
Enrollment
380
Registered
2017-04-21
Start date
2016-06-30
Completion date
2017-03-25
Last updated
2021-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trauma

Brief summary

This is a prospective, non-blinded, non-randomized, interventional study of the Masimo pulse oximeter and sensors in a trauma setting

Detailed description

The study aimed to evaluate SpHb's ability to detect critical drops in a trauma population

Interventions

DEVICERadical-7 Pulse CO-Oximeter and sensor

Noninvasive device that measures hemoglobin.

Sponsors

Masimo Corporation
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Estimated 16 years of age or older or greater than or equal to 50 kg body weight if age unknown. * Level 1 (highest trauma activation) status at the time of arrival to emergency department (ED). * Expected to be admitted to the ICU/IMU for in hospital care.

Exclusion criteria

* Moribund patients with devastating injuries and expected to die within one hour of ED admission. * Prisoners, as defined as those who have been directly admitted from a correctional facility (a free living individual who is under police observation as a suspect will remain in the study until hospital discharge). * Obvious pregnancy in the ED. * Received greater than 5 minutes of cardiopulmonary resuscitation (CPR) in the pre-arrival or hospital setting. * Has, on the ring, middle and index fingers of both hands, any of the following: finger deformities, injuries, including burns, scar tissue or infection, or any material that may interfere with sensor application or trans-illumination of the site. * Has significant bilateral trauma to the arms or forearms.

Design outcomes

Primary

MeasureTime frameDescription
SpHb's Ability to Detect Critical DropsUp to 24 hours.The ability of noninvasive continuous total hemoglobin (SpHb) to detect critical drops in arterial or venous hemoglobin values, calculated using chi-squared analysis.

Countries

United States

Participant flow

Participants by arm

ArmCount
Test Subjects
Each test subject will receive a Radical-7 Pulse CO-Oximeter and sensor that will remain on the subject for the first 24 hours following ED admission or discharge from the ICU/IMU. Radical-7 Pulse CO-Oximeter and sensor: Noninvasive device that measures hemoglobin.
351
Total351

Baseline characteristics

CharacteristicTest Subjects
Age, Categorical
<=18 years
24 Participants
Age, Categorical
>=65 years
33 Participants
Age, Categorical
Between 18 and 65 years
294 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Asian
7 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Black or African American
95 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Hispanic/Latino
92 Participants
Race/Ethnicity, Customized
Race/Ethnicity
More than one race
1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Other
1 Participants
Race/Ethnicity, Customized
Race/Ethnicity
Unknown or Not Reported
3 Participants
Race/Ethnicity, Customized
Race/Ethnicity
White
152 Participants
Sex: Female, Male
Female
70 Participants
Sex: Female, Male
Male
281 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
1 / 351
other
Total, other adverse events
0 / 351
serious
Total, serious adverse events
0 / 351

Outcome results

Primary

SpHb's Ability to Detect Critical Drops

The ability of noninvasive continuous total hemoglobin (SpHb) to detect critical drops in arterial or venous hemoglobin values, calculated using chi-squared analysis.

Time frame: Up to 24 hours.

Population: Sufficient number of cases to meet sample size criteria for assessing outcomes was not achieved. The protocol required a minimum of 50 subjects with at least 2 blood samples to conduct an interim analysis to calculate final sample size in order to obtain to a definition of critical drop detection. This study was not able to meet this target and therefore a critical drop could not be defined (primary outcome measure).

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026